Journal of Genetic Syndromes & Gene Therapy
Open Access

Tay-Sachs Disease: Understanding the Devastating Impact and Advances in Research

William Oren^{* *}Correspondence: William Oren, Department of Global Health, Boston University School of Public Health, Boston, USA, Email:

Author info »

Description

Tay-Sachs disease is a rare, inherited disorder characterized by the progressive degeneration of nerve cells in the brain and spinal cord. This devastating disease primarily affects infants, leading to severe neurological impairments and a shortened lifespan. Tay-Sachs is caused by a mutation in the HEXA gene, resulting in a deficiency of the enzyme hexosaminidase A (Hex A). As our understanding of the genetic basis and clinical manifestations of Tay-Sachs has evolved, so too have research efforts aimed at developing improved diagnostics, treatment options, and support for affected individuals and their families [1].

Genetic basis of tay-Sachs

Tay-Sachs disease is an autosomal recessive disorder, meaning that both parents must carry a copy of the mutated HEXA gene for a child to develop the condition. The HEXA gene provides instructions for producing the Hex A enzyme, which plays a crucial role in breaking down a fatty substance called GM2 ganglioside. In individuals with Tay-Sachs, the deficiency of Hex A leads to the accumulation of GM2 ganglioside in the nerve cells of the brain, resulting in progressive damage and the characteristic symptoms of the disease [2, 3].

Clinical manifestations

Tay-Sachs disease primarily affects the central nervous system, leading to a range of devastating neurological symptoms. Infants with Tay-Sachs typically appear healthy at birth, but symptoms become apparent between three and six months of age. These symptoms can include developmental regression, loss of motor skills, muscle weakness, an exaggerated startle response to loud noises, vision and hearing impairments, and seizures. As the disease progresses, infants lose the ability to crawl, sit, or swallow, and eventually become immobile, unresponsive, and require around-the-clock care [4, 5].

The challenges faced by individuals and families affected by Tay-Sachs are immense. The emotional toll of witnessing the progressive deterioration of a child's health, coupled with the demanding physical and financial burden of caregiving, can be overwhelming. Genetic counseling, mental health support, and access to specialized medical and therapeutic services are crucial to navigating these challenges [6, 7].

Advancements in treatments

While there is currently no cure for Tay-Sachs disease, scientific advancements and research efforts are offering hope for improved diagnostics and potential treatments. Prenatal testing and carrier screening have become standard practice, allowing for early identification of couples at risk and informed family planning decisions. Advances in genetic testing techniques, including next-generation sequencing, enable more accurate and timely diagnosis [8, 9].

Research is also focused on potential treatments for Tay-Sachs, including Enzyme Replacement Therapy (ERT) and gene therapy approaches. ERT involves the administration of synthetic Hex A enzyme to compensate for the deficiency and reduce the accumulation of GM2 ganglioside. Gene therapy aims to deliver a functional HEXA gene to affected cells, restoring the production of the missing enzyme. While these treatment modalities are still in the experimental stage, early results from preclinical and clinical studies show promise, sparking hope for potential future therapies [10].

Conclusion

Tay-Sachs disease remains a devastating disorder with profound effects on affected individuals and their families. However, advancements in research and diagnostics have enhanced our understanding of the disease and offer potential avenues for future treatments. Continued research, support, and advocacy are vital in improving the lives of those impacted by Tay-Sachs and working towards a future free of this devastating disease.

References

1. Myerowitz R. Tay-Sachs disease‐causing mutations and neutral polymorphisms in the Hex A gene. Hum Mutat. 1997;9(3):195-208.

   [Crossref] [Google Scholar] [PubMed]

2. Dersh D, Iwamoto Y, Argon Y. Tay–Sachs disease mutations in HEXA target the α chain of hexosaminidase A to endoplasmic reticulum–associated degradation. Mol Biol Cell. 2016;27(24):3813-3827.

   [Crossref] [Google Scholar] [PubMed]

3. Hechtman P, Kaplan F. Tay–Sachs disease screening and diagnosis: evolving technologies. DNA Cell Biol.1993;12(8):651-665.

   [Crossref] [Google Scholar] [PubMed]

4. Hussein N, Henneman L, Kai J, Qureshi N. Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay‐Sachs disease. Cochrane Database Syst Rev. 2021(10).

   [Crossref] [Google Scholar] [PubMed]

5. Okada S, Taniike M. Tay-Sachs disease (beta-hexosaminidase alpha-chain deficiency). Ryoikibetsu Shokogun Shirizu. 1998;19(2):394-396.

   [Google Scholar]

6. Koeslag, JH, Schach, SR & Melzer CW. Tay-Sachs disease and the persistence of lethal autosomal recessive genes in human populations. S Afr  Med J. 1984;66(3):87-89.

   [Crossref] [Google Scholar] [PubMed]

7. Riboldi GM, Lau H. Diagnostic Tips from a Video Series and Literature Review of Patients with Late-Onset Tay-Sachs Disease. Tremor Other Hyperkinet Mov. 2022;12(1).

   [Crossref] [Google Scholar] [PubMed]

8. Bibi F, Ullah A, Bourinaris T, Efthymiou S, Kriouile Y, Sultan T, et al. Tay-Sachs disease: Two novel rare HEXA mutations from Pakistan and Morocco. Klin Pädiatr. 2021;233(05):226-230.

   [Crossref] [Google Scholar] [PubMed]

9. Sutton VR. Tay-Sachs disease: Screening and counseling families at risk for metabolic disease. Obstet  Gynecol Clin North Am. 2002;29(2):287-296.

   [Crossref] [Google Scholar] [PubMed]

10. Májovská J, Hennig A, Nestrasil I, Schneider SA, Jahnová H, Vaněčková M, et al. Pontocerebellar atrophy is the hallmark neuroradiological finding in late-onset Tay-Sachs disease. Neurol Sci. 2022:1-9.

    [Crossref] [Google Scholar] [PubMed]